REFERENCES
2. Soliman H, Ringash J, Jiang H, et al. Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. J Clin Oncol 2013;31:3980-6.
3. Wong TC, Lee VH, Law AL, et al. Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant. Hepatology 2021;74:2580-94.
4. Mathew AS, Dawson LA. Current understanding of ablative radiation therapy in hepatocellular carcinoma. J Hepatocell Carcinoma 2021;8:575-86.
5. Murray LJ, Dawson LA. Advances in stereotactic body radiation therapy for hepatocellular carcinoma. Semin. Radiat Oncol 2017;27:247-55.
6. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022;76:681-93.
7. Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol 2018;69:182-236.
8. Rasic G, de Geus SWL, Papageorge MV, et al. Disparities in the receipt of recommended curative treatment for patients with early-stage hepatocellular carcinoma. World J Surg 2023;47:1780-89.
9. Hasan S, Abel S, Jan I, Uemura T, Thai N, Kirichenko AV. The albumin-bilirubin (ALBI) model in hepatocellular carcinoma (HCC) may better predict hepatic failure in patients with traditionally low-risk cirrhosis following definitive stereotactic body radiotherapy (SBRT). J Radiat Oncol 2018:7, 247-53.
10. Su TS, Yang HM, Zhou Y, et al. Albumin - bilirubin (ALBI) versus child-turcotte-pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy. Radiat Oncol 2019;14:50.
11. Moon DH, Wang AZ, Tepper JE. A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy. Radiother Oncol 2018;126:527-33.
12. Kielar A, Fowler KJ, Lewis S, et al. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY) 2018;43:218-30.
13. Apisarnthanarax S, Barry A, Cao M, et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract Radiat Oncol 2022;12:28-51.
14. Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78:1922-65.
15. Yanagihara TK, Tepper JE, Moon AM, et al. Defining minimum treatment parameters of ablative radiation therapy in patients with hepatocellular carcinoma: an expert consensus. Pract Radiat Oncol 2024;14:134-45.
16. Moon AM, Kim HP, Singal AG, et al. Thermal ablation compared to stereotactic body radiation therapy for hepatocellular carcinoma: a multicenter retrospective comparative study. Hepatol Commun 2023;7:e00184.
17. Kimura T, Takeda A, Tsurugai Y, et al. A multi-institutional retrospective study of repeated stereotactic body radiation therapy for intrahepatic recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2020;108:1265-75.
18. Roquette I, Bogart E, Lacornerie T, et al. Stereotactic body radiation therapy for the management of hepatocellular carcinoma: efficacy and safety. Cancers (Basel) 2022;14:3892.
19. Hong TS, Wo JY, Yeap BY, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016;34:460-8.
20. Weiss J, Vincent B, Deal A, et al. Progression-free survival, overall survival and immunophenotyping outcomes for patients with stage III-IV head and neck cancer and cisplatin contraindication treated with definitive radiotherapy plus pembrolizumab. Int J Radiat Oncol Biol Phys 2020;106:1221.
